iShares MSCI Australia ETF vs Medtronic PLC — how do they compare? iShares MSCI Australia ETF trades at $29.94, while Medtronic PLC trades at $90.59 (market cap $114.45B). The key difference: Medtronic PLC pays a 3.22% dividend while iShares MSCI Australia ETF pays none, and iShares MSCI Australia ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| EWA | MDT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $105.35 |
52-Week Low | $24.95 | $73.75 |
Market Cap | — | $114.45B |
Enterprise Value | — | $133.19B |
Dividend Yield | — | 3.22% |
Signals from Pluang's Aura AI — not financial advice
EWA trades at $30.41, up 0.83% with a bullish technical bias from moving averages, though oscillators signal caution with RSI levels above 70 indicating potential overbought conditions. The stock shows strong momentum with ADX readings above 36, while support and resistance cluster near $30-$31. Recent corporate actions include a scheduled dividend of $0.40 per share for June 2026.
Outlook remains positive given technical strength, but elevated RSI warrants monitoring for pullbacks. Risks include macroeconomic sensitivity and sector competition. Investment appeal hinges on sustained earnings growth and dividend stability, with current levels offering limited upside near resistance.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →